1-(3-pyridinyl)-2,3,4,9-tetrahydro-1H-beta-carboline-3-carboxylic acid

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 1-(3-pyridinyl)-2,3,4,9-tetrahydro-1H-beta-carboline-3-carboxylic acid
• 英文别名: 1-pyridin-3-yl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-ium-3-carboxylate
• 化学式: C₁₇H₁₅N₃O₂
• 分子量: 293.325
• InChiKey: XQRUJLXAOIVJQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  78
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3-pyridinyl)-2,3,4,9-tetrahydro-1H-beta-carboline-3-carboxylic acid 在 硫酸 、 二甲基亚砜 作用下， 生成 methyl 1-( pyridin-3-yl)-9H-pyrido[3,4-b]indole-3-carboxylate
  参考文献：
  名称：

  二甲基亚砜将1-芳基（杂芳基）-1,2,3,4-四氢-9 H-β-咔啉-3-羧酸及其酯脱氢

  摘要：

  1-芳基（杂芳基）-1,2,3,4-四氢-9-氧化脱氢Н -β-β-咔啉-3-羧酸的衍生物与二甲亚砜通向1-芳基（杂芳基）-9形成Н - β-咔啉。与脱氢同时发生脱羧。在用甲基1-芳的二甲亚砜（杂芳基）-1,2,3,4-四氢-9-氧化Н -β-β-咔啉-3- carboxylicates甲基-1-芳基（杂芳基）-9- Н -β咔啉形成3-羧酸盐，其水解得到相应的1-芳基（杂芳基）-9Н -β-咔啉-3-羧酸。

  DOI：

  10.1134/s1070428016110117
• 作为产物：
  描述：

  3-吡啶甲醛 、 L-色氨酸 在 溶剂黄146 作用下， 生成 1-(3-pyridinyl)-2,3,4,9-tetrahydro-1H-beta-carboline-3-carboxylic acid
  参考文献：
  名称：

  新型N 9-异二价β-咔啉类化合物作为血管生成抑制剂的合成及生物学评价

  摘要：

  抽象的 已经合成了一系列新颖的N 9-杂二价β-咔啉。测试了所有这些新化合物对六种肿瘤细胞的体外抗癌活性。在这些分子中，化合物5b和5w表现出强大的细胞毒性活性，IC 50值低于20μM。还评估了所选化合物在小鼠中的急性毒性和抗肿瘤功效，化合物5b和5w在肉瘤180和Lewis肺癌动物模型中显示出超过40％的肿瘤抑制率。初步的结构-活性关系（SAR）分析表明：（1）C 1-甲基化和C 7-甲氧基化有助于增加活性；（2）在β-咔啉核心的位置1上的3-吡啶基或2-噻吩基取代基，以及在另一个β-咔啉环上的芳基取代基可能对这类化合物的细胞毒性作用有害。对初步作用机理的研究表明，化合物5b在鸡绒膜尿囊膜（CAM）分析中具有明显的血管生成抑制作用。

  DOI：

  10.1080/14756366.2018.1497619

文献信息

• Synthesis and structure-activity relationships of asymmetric dimeric β-carboline derivatives as potential antitumor agents
  作者：Liang Guo、Wei Chen、Rihui Cao、Wenxi Fan、Qin Ma、Jie Zhang、Bin Dai

  DOI：10.1016/j.ejmech.2018.02.003

  日期：2018.3

  series of newly asymmetric dimeric β-carbolines with a spacer of 4–6 methylene units between the indole nitrogen and the harmine oxygen were synthesized. Structures of all the novel synthesized compounds were confirmed by their spectral and analytical studies. All of the synthesized compounds were screened for their in vitro cytotoxic activity against nine cancer cell lines. The results revealed that

  合成了一系列新的不对称的二聚β-咔啉，它们在吲哚氮和氨苄基氧之间具有一个4-6个亚甲基单元的间隔。通过光谱和分析研究证实了所有新型合成化合物的结构。筛选所有合成的化合物对九种癌细胞系的体外细胞毒活性。结果表明，化合物7c，7o和7s对测试的肿瘤细胞系表现出最高的细胞毒活性，IC 50值小于20μM。还评估了所选化合物在小鼠中的急性毒性和抗肿瘤功效，并且化合物7o表现出有效的抗肿瘤活性，肿瘤抑制率超过40％。伤口愈合试验显示了HT-29细胞运动性的特定损伤，这提示了化合物7o的抗转移潜力。此外，化合物7o在鸡绒膜尿囊膜（CAM）分析中具有明显的血管生成抑制作用。初步的结构-活性关系（SAR）分析表明：（1）吲哚环N 9位的3-苯基丙基取代基是最合适的产生有效细胞毒性剂的基团；（2）间隔物长度影响抗肿瘤能力，并且四个亚甲基单元是更有利的。
• COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF
  申请人：CYTUS H&B CO., LTD.

  公开号：US20200354327A1

  公开（公告）日：2020-11-12

  The present invention relates to a compound exhibiting STAT3 inhibitory activity, or a pharmaceutically acceptable salt, solvate or hydrate of the same, and pharmaceutical uses of these. The compounds of the present invention efficiently inhibit the abnormal activity of STAT3 associated with various diseases and thus can be usefully utilized for the prevention and treatment of various STAT3-related diseases associated with cancer, autoimmune diseases, inflammatory diseases and the like.

  本发明涉及一种具有STAT3抑制活性的化合物，或其药学上可接受的盐、溶剂或水合物，以及这些化合物的药物用途。本发明的化合物有效地抑制了与各种疾病相关的STAT3异常活性，因此可用于预防和治疗与癌症、自身免疫性疾病、炎症性疾病等相关的各种STAT3相关疾病。
• BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：XINJIANG HUASHIDAN PHAR MACEUTICAL RESEARCH CO., LTD

  公开号：US20160039845A1

  公开（公告）日：2016-02-11

  Disclosed in the present invention are a bis-β-carboline compound and a preparation method, a pharmaceutical composition and the use thereof. In particular, the bis-β-carboline compound and a pharmaceutical salt thereof are described as general formula I, and the bis-β-carboline compound is prepared through the condensation of β-carboline intermediate and dihaloalkane. Also disclosed in the present invention are a pharmaceutical composition comprising an effective dose of the bis-β-carboline compound as shown in formula I and a pharmaceutically acceptable carrier, and the use of the bis-β-carboline compound in preparing drugs resistant to tumours such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer.

  本发明公开了一种双β-咔唑化合物及其制备方法、药物组合物及其用途。其中，描述了双β-咔唑化合物及其药物盐的一般式I，双β-咔唑化合物是通过β-咔唑中间体和二卤代烷的缩合反应制备而成。本发明还公开了一种药物组合物，包括一定剂量的公式I所示的双β-咔唑化合物和药学上可接受的载体，并且公开了将双β-咔唑化合物用于制备对肿瘤具有抗药性的药物，如黑色素瘤、胃癌、肺癌、乳腺癌、肾癌、肝癌、口腔表皮癌、宫颈癌、卵巢癌、胰腺癌、前列腺癌和结肠癌。
• BIS- -CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Xinjiang Huashidan Pharmaceutical Research Co., Ltd.

  公开号：EP2924042A1

  公开（公告）日：2015-09-30

  Disclosed in the present invention are a bis-β-carboline compound and a preparation method, a pharmaceutical composition and the use thereof. In particular, the bis-β-carboline compound and a pharmaceutical salt thereof are described as general formula I, and the bis-β-carboline compound is prepared through the condensation of β-carboline intermediate and dihaloalkane. Also disclosed in the present invention are a pharmaceutical composition comprising an effective dose of the bis-β-carboline compound as shown in formula I and a pharmaceutically acceptable carrier, and the use of the bis-β-carboline compound in preparing drugs resistant to tumours such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer.

  本发明公开了一种双-β-咔啉化合物及其制备方法、药物组合物和用途。其中，所述双-β-咔啉化合物及其药物盐为通式Ⅰ，双-β-咔啉化合物是通过β-咔啉中间体和二卤代烷烃缩合制备的。本发明还公开了一种药物组合物，该组合物包含有效剂量的式 I 所示的双-β-咔啉化合物和药学上可接受的载体，以及双-β-咔啉化合物在制备抗肿瘤药物中的用途，如黑色素瘤、胃癌、肺癌、乳腺癌、肾癌、肝癌、口腔表皮癌、宫颈癌、卵巢癌、胰腺癌、前列腺癌和结肠癌。
• Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof
  申请人：XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD.

  公开号：US10011614B2

  公开（公告）日：2018-07-03

  Disclosed in the present invention are a bis-β-carboline compound and a preparation method, a pharmaceutical composition and the use thereof. In particular, the bis-β-carboline compound and a pharmaceutical salt thereof are described as general formula I, and the bis-β-carboline compound is prepared through the condensation of β-carboline intermediate and dihaloalkane. Also disclosed in the present invention are a pharmaceutical composition comprising an effective dose of the bis-β-carboline compound as shown in formula I and a pharmaceutically acceptable carrier, and the use of the bis-β-carboline compound in preparing drugs resistant to tumors such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer.

  本发明公开了一种双-β-咔啉化合物及其制备方法、药物组合物和用途。其中，双-β-咔啉化合物及其药用盐描述为通式 I，双-β-咔啉化合物是通过 β-咔啉中间体和二卤代烷烃缩合制备的。本发明还公开了一种药物组合物，该组合物包含有效剂量的式 I 所示的双-β-咔啉化合物和药学上可接受的载体，以及双-β-咔啉化合物在制备抗肿瘤药物中的用途，如黑色素瘤、胃癌、肺癌、乳腺癌、肾癌、肝癌、口腔表皮癌、宫颈癌、卵巢癌、胰腺癌、前列腺癌和结肠癌。